Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medilink Therapeutics (Suzhou) Co. Ltd.
Headquarters: Suzhou, China
Website: https://www.medilinkthera.com/...
Year Founded: 2020
Status: Private
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Nov 14, 2024
Deals
Already partners on bispecific, BioNTech buys Biotheus for $800M
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
BioCentury | Oct 1, 2024
Deals
Prime narrows gene editing focus with BMS deal
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | Aug 20, 2024
Product Development
Clinical Report: Lilly’s tirzepatide shows benefit in pre-diabetics
Plus: Updates on BioNTech, MediLink, Pfizer and Incyte
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | May 14, 2024
Data Byte
The diverse modalities targeting B7-H3
ADCs against the target have raised safety concerns, but companies are hitting B7-H3 with other modalities
BioCentury | Jan 3, 2024
Deals
Jan. 2 Quick Takes: Latest Novartis collaboration lifts Voyager’s value
Plus: Longboard triples on strength of anticonvulsive readout and updates from Anavex, Roche-MediLink, Allorion-AstraZeneca and more
BioCentury | Nov 9, 2023
Deals
China’s strength is innovation on innovation. Western partners are lining up
Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive
BioCentury | Oct 31, 2023
Management Tracks
CSO, CFO changes at Third Harmonic
Plus: MediLink hires Steve Chin as CMO, and updates from ImmPACT,
BioCentury | May 7, 2022
Finance
Lyfe lessons: Bay Area VC growing global footprint with $935M new fund
With its roots in China, Lyfe Capital will continue to build bridges between its Western and Asian therapeutics, diagnostics and medtech plays
Items per page:
1 - 10 of 11